Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Omeros obtains approvals to begin phase I trial with PDE7 inhibitor OMS-527

June 28, 2018

DSMB of Aladote phase Ib/IIa study to treat paracetamol poisoning finds no safety concerns

June 25, 2018

Braeburn resubmits CAM-2038 NDA for opioid use disorder to FDA

May 28, 2018

FDA approves Lucemyra to mitigate opioid withdrawal symptoms

May 17, 2018

New phase II proof-of-concept trial studies IXT-m200 in methamphetamine users

May 11, 2018

Researchers present nanoencapsulated hepatocyte enzymes to fight alcohol intoxication

May 11, 2018

FDA clears Pluristem's IND application for PLX-R18 to treat acute radiation syndrome

May 2, 2018

Accelerator Life Science Partners launches Proniras

April 30, 2018

Researchers present gene therapy for methamphetamine-induced inflammation

April 27, 2018

Pear Therapeutics and Sandoz sign agreement for prescription digital therapeutics

April 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...